Short-term immunotherapy with tree pollen allergoids and the adjuvant monophosphoryl lipid-A - Results from a multicentre, placebo-controlled, randomised, double-blind study;Kurzzeit-immuntherapie mit baumpollen-allergoiden und dem adjuvans monophosphoryl lipid-A: Ergebnisse einer randomisierten, doppelblinden, plazebokontrollierten multicenterstudie

Allergologie

Volumn 25, Issue 9, 2002, Pages 466-474

  Drachenberg, K J ^a   Heinzkill, M ^a   Urban, E ^a  

^a Bencard Allergie GmbH   (Germany)

Author keywords

Adjuvant; Allergoids; Asthma; Conjunctivitis; Monophosphory lipid A; MPL; Rhinitis; Short term immunotherapy; Tree pollen

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PHOSPHORYL LIPID A; PLACEBO; POLLEN ANTIGEN; TYROSINE;

ADSORPTION; ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGLOBULIN PRODUCING CELL; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLLEN ALLERGY; PRICK TEST; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; URTICARIA;

EID: 0036750172     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: 10.5414/alp25466     Document Type: Article

References (31)

1. Bousquet J., R.F. Lockey, H.-J. Malling: Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. Allergy 53 (Suppl.), 1-42 (1998).
2. Akdis C.A., K. Blaser: Mechanisms of specific immunotherapy. Allergy 55, 522-530 (2000).
3. Baldridge J.R., Y. Yorgensen, J.R. Ward, J.T. Ulrich: Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18, 2416-2425 (2000).
4. Des Roches A., L. Paradis, J.-L. Ménardo, S. Bouges, J.-P. Daurés, J. Bousquet: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitisations in children. J. Allergy Clin. Immunol. 99, 450-453 (1997).
5. Drachenberg K.J., A.W. Wheeler, P. Stuebner, F. Horak: A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A reduces allergic symptoms after only four preseasonal injections. Allergy 56, 498-505 (2001).
6. Durham S.R., S.J. Till: Immunologic changes associated with allergen immunotherapy. J. Allergy Clin. Immunol. 102, 157-164 (1998).
7. Durham S.R., S.M. Walker, E.M. Varga, M.R. Jacobson, F. O'Brien, W. Noble, S.J. Till, Q.A. Hamid, K.T. Nouri-Aria: Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341, 468-475 (1999).
8. Grüber C., L. Nilsson, B. Björksten: Do early childhood immunizations influence the development of atopy and do they cause allergic reactions? Pediatr. Allergy Immunol. 12, 296-311 (2002).
9. Gustafson G.L., M.J. Rhodes: Early interferon-γ as a marker for adjuvants that enhance protective immunity. Res. Immunol. 143, 483-488 (1990).
10. Heppner D.G., G.M. Gordon, M. Gross: Safety, immunogenicity and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J. Infect. Dis. 174, 361-366 (1996).
11. Johansson S.G., A.C. Miller, N. Mullan, B.G. Overell, E.C. Tees, A. Wheeler: Glutaraldehyde-pollen-tyrosine: clinical and immunological studies. Clin. Allergy 4, 255-263 (1974).
12. Kleine-Tebbe J., T. Fuchs, L. Klimek, J. Kühr, U. Lepp, B. Niggemann, J. Rakoski, H. Renz, J. Saloga, J. Simon: Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen. Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Immunologie. Allergo J. 9, 317-324 (2000).
13. Klimek L., B. Stuck, J. Hundorf, S. Schneider-Gene, K. Hörmann: Monophosphoryl lipid A (MPL) has TH1 stimulating properties in immunotherapy with birch allergoid. Allergy 56 (Suppl. 68), 93 (2001).
14. Koutsoukos M., G. Leroux, E.P. Vandepapelier, M. Slaoui, P. Pala: Induction of cell-mediated immune responses in man with vaccines against Herpes simplex virus based on glycoprotein D. 34th ICAAC meeting 1994, M8, 217.
15. Lüderitz-Püchel U., B. Keller-Stanislawski, D. Haustein: Neubewertung des Risikos von Testund Therapieallergenen. Bundesgesundheitsbl. Gesundheitsforsch. Gesundheitsschutz 44, 709-718 (2001).
16. Malling, H.-J., J. Abreu-Nogueira, E. Alvarez-Cuesta, B. Björkstén, J. Bousquet, D. Caillot, W. Canonica, G. Passalacqua, P. Saxonis-Papageorgiou, E. Valovirta: Position paper (EAA-CI/ESPACI) - local immunotherapy. Allergy 53, 933-944 (1998).
17. Mikloska Z., M. Rückholdt, I. Ghadiminejad, H. Dunckly, M. Denis, A.L. Cunningham: Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to Herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J. Immunol. 164, 5167-5176 (2000).
18. Mitchell M.S.: Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin. Oncol. 25, 623-635 (1998).
19. Moller C., S. Dreborg, H.A. Ferdousi, S. Halken, A. Host, L. Jacobsen, A. Koivikko, D. Y. Koller, B. Niggemann, L.A. Noerberg, R. Urbanek, E. Valovirta, U. Wahn.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT Study). J. Allergy Clin. Immunol. 109, 251-256 (2002).
20. Moran D.M., A.W. Wheeler, B.G. Overell, S.R. Woroniecki: Chemical modification of crude timothy grass extract. 3. The effect of glutaraldehyde-induced aggregation on antigenic and immunogenic properties. Int. Arch. Allergy Appl. Immunol. 54, 315-321 (1977).
21. Negro J.M., A.W. Wheeler, J. Hernandez, L.J. Youlten, A. Pascual, F.J. Garcia-Selles, J.A. Pagan, J.D. Lopez-Sanchez, J.C. Miralles, F. Sarrio, J.M. Milan, L.G. Contreras, D. Vidal: Comparison of the efficacy and safety of two preseasonal regimes of glutaraldehyde modified, tyrosine-adsorbed parietria pollen extract over a period of three years in monosensitive patients. Allergol. Immunopathol. 27, 153-164 (1999).
22. Newman K.D., D.L. Sowsnowski, G.S. Kwon, J. Samuel: Delivery of MUC1 mucin peptide by poly(d,l-lactic-co-glycolic acid)microspheres induces type 1 helper immune responses. J. Pharm. Sci. 87, 1421-1427 (1998).
23. Overell B.G., D.A. Spackmann, A.W. Wheeler, P. Pfeiffer: Standardisation of glutaraldehyde-modified, tyrosine-adsorbed allergen extracts. Allergologie 14. 110-115 (1991).
24. Secrist H., C.J. Chelen, Y. Wen, J.D. Marshall, D.T. Umetsu: Allergen immunotherapy decreases interleukin 4 production in CD4+ cells from allergic individuals. J. Exp. Med. 178, 2123-2130 (1993).
25. Thoelen S.: An overview on a novel adjuvanted prophylactic hepatitis B vaccine. Acta Gastroenterol. Belg. 63, 185-186 (2000).
26. Thoelen S., P. van Damme, C. Mathei, G. Leroux-Roels, I. Desombere, A. Safary, P. Vandepapeliere, M. Slaoui, A. Meheus: Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16, 708-714 (1998).
27. Ulrich J.T., A.W. Wheeler: Allergen formulation. 1998 World patent (PCT) WO 98/44947.
28. Wheeler A.W., I.H. Taylor, V. Mehta, J. Mitchell, D. Reece, K.J. Drachenberg: Tyrosin-Allergoid Baumpollen. Standardisierung mittels relevanter Methoden. Allergo J. 2, 71-75 (1993).
29. Wheeler A.W., T. Ulrich, J. Marshall: A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol. 126, 135-139 (1998).
30. Wheeler A.W., S.W. Woroniecki: Immunological adjuvants in allergy vaccines: Past, present and future. Allergol. Int. 50, 295-301 (2001).
31. Whittall N., D.M. Moran, A.W. Wheeler, G.P. Cottam: Suppression of murine IgE responses with poly-(n-methylglycine)/grass pollen extract conjugates using 4-(methylmercapto)phenyl-succinimidyl succinate as coupling reagent. Int. Arch. Allergy Appl. Immunol. 76, 354-360 (1985).